Non-Invasive Imaging for the Evaluation of a New Oral Supplement in Skin Aging: A Case-Controlled Study.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

Skin aging represents a para-physiological process related to metabolic imbalances, inflammation, proliferative responses, and oxidative stress.

Ending the cycle of inflammation, and oxidative stress represents a way to slow the effects of aging.

Who Took Part

The abstract describes 40 participants taking part.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

A prospective clinical study was conducted in 40 participants.

They were randomized 1:1 to receive the supplement (Giovina) or placebo.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

What Was Measured

PubMed files the paper under topics including Skin Aging, Tomography, Optical Coherence, Dietary Supplements, Case-Control Studies and Skin.

The authors tagged it with the keywords antioxidant, collagen, food supplement, inflammatory aging and wrinkle.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Copper (Supplement) in 40 participants.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.